Dear Doctor Letter (Rote-Hand-Brief) on medicinal products containing temozolomide: risk of severe liver toxicity
2013.12.13
Active substance: temozolomide
The companies concerned point out that cases of liver injury, including liver failure with lethal outcome, have been reported in patients treated with medicinal products containing temozolomide. The liver toxicity may not appear until several weeks or more after the beginning of therapy or after stopping the treatment with temozolomide. Therefore, liver function tests should be carried out at specified times.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN